Efficiency of 177Lu-DOTA-FAPI Therapy in Treatment of Patients With Various Types of Cancer (Primary Locally Advanced or Metastatic Cancers)

Boushehr University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新: 2021年11月1日

适应症

试验速览

暂无简介。

•The presence of at least one tumoral lesion detected by 68Ga-DOTA-FAPI PET/CT or 99mTc-DOTA-FAPI SPECT
•Having hematologic parameters as: (i) Absolute neutrophil count = 1000 cells/mm3; (ii) Platelet count = 100,000/mm3; (iii) Hemoglobin = 8 g/dL
•Participants who sign the informed consent form which was assented according to the guidelines of the Clinical Research Ethics Committee (signed by participant, parent, or legal representative).
•Eastern Cooperative Oncology Group Performance Status (ECOG) = 2

•Patient had history of class 3 or 4 congestive heart failure (CHF)
•Patient had clinically significant bleeding within two weeks prior to trial entry (e.g. gastrointestinal bleeding, intracranial bleeding)
•Pregnant or lactating women
•Patient have psychiatric illness/social situations that would interfere with compliance with study requirements
•Patient cannot undergo PET/CT or SPECT scanning because of weight limits
•Patient had an active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.

发起方

Boushehr University of Medical Sciences